Amyloid-Beta Binding Peptides and Their Use for the Therapy and Diagnosis of Alzheimer's Dementia

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a set of specifically designed peptides that selectively bind to certain forms of amyloid-beta proteins, particularly monomeric amyloid-beta, which are implicated in the development and progression of Alzheimer's disease. These peptides can be used for both therapeutic and diagnostic purposes: as drugs to prevent or treat Alzheimer's dementia by stabilizing amyloid-beta monomers and reducing toxic amyloid-beta oligomers, and as probes for detecting amyloid-beta species in biological samples.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic use as drugs to treat or prevent Alzheimer's disease by inhibiting the formation of toxic amyloid-beta oligomers and aggregates.
• Diagnostic use as molecular probes in imaging and laboratory assays (e.g., ELISA, SPECT, PET, MRI) to detect, quantify, or monitor amyloid-beta species in patients' tissues or fluids.
• Development of blood treatment kits or devices (e.g., for blood/plasma apheresis) to remove or detoxify amyloid-beta oligomers outside the body (ex vivo).
• Research tools for studying the aggregation behavior and toxicity of amyloid-beta in laboratory models of Alzheimer's disease.
• Potential incorporation into food supplements or preventive pharmaceutical formulations for at-risk populations.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific binding to amyloid-beta monomers avoids reduction of beneficial monomer forms, focusing action on toxic oligomers—potentially reducing side effects.
• The peptides can both prevent formation of new toxic amyloid-beta oligomers and convert existing toxic oligomers into harmless forms or monomers, offering a dual mode of action.
• Peptides are designed to be composed mainly of D-amino acids or cyclized forms, making them more stable in the body and less likely to be degraded by natural enzymes.
• Potential for early diagnosis and monitoring of Alzheimer's disease progression through sensitive and specific detection of amyloid-beta species.
• Expandable and adaptable platform for the development of kits, compositions, or therapies tailored to individual or clinical needs.
• Improved efficacy and selectivity over previous amyloid-beta targeting approaches by using a novel identification and selection method (modified mirror-image phage display).

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to specific amyloid beta binding peptides and to the use of same for treating and diagnosing Alzheimer's dementia.